
RxPreferred’s Jeff Malone Featured in MedHealth Outlook’s PBM Issue
Three traditional pharmacy benefit managers (PBMs), often referred to as the “Big 3”, control over 80% of the prescriptions across the US, while the majority of employers struggle to keep healthcare affordable for their employees and covered members.

RxPreferred Named to RxInsider’s Inaugural 2024 Pharmacy500 List
RxPreferred, a transparent Pharmacy Benefit Manager (PBM) is proud to announce its inclusion in the prestigious 2024 Pharmacy500 list presented by RxInsider

Independent Pharmacy Spotlight Conversation: With Mark Cuban Cost Plus Drug Company & RxPreferred
RxPreferred News Subscribe Independent Pharmacy Spotlight Conversation: With Mark Cuban Cost Plus Drug Company & RxPreferred

Mark Cuban Cost Plus Drug Company & RxPreferred on PBMs, Transparency, and Transforming Healthcare
RxPreferred News Subscribe Mark Cuban Cost Plus Drug Company & RxPreferred on PBMs, Transparency, and Transforming Healthcare

RxPreferred Benefits Unveils Enhanced Member Portal for Streamlined Healthcare Management
RxPreferred News Subscribe RxPreferred Benefits Unveils Enhanced Member Portal for Streamlined Healthcare Management NASHVILLE, Tenn., March 26, 2024 /PRNewswire/ — RxPreferred, a premier Pharmacy Benefits Administrator, is thrilled to announce the debut of its upgraded Member Portal, aimed at revolutionizing the member experience with seamless navigation and advanced tracking capabilities. “Our enhanced Member Portal reflects our dedication to transforming healthcare and the member experience by empowering our members to take control of

RxPreferred flips the script on rising healthcare costs with Mark Cuban Cost Plus Drug Company
RxPreferred News Subscribe RxPreferred flips the script on rising healthcare costs with Mark Cuban Cost Plus Drug Company, offering Humira® Biosimilar, YUSIMRY™, to plans and members. RxPreferred’s inclusion of YUSIMRY™ will have a significant impact on employersponsored health plans and their members with the biosimilar representing a 92% discount from the list price for Humira®. The blockbuster move will improve access to medication for patients that previously could not afford